Galderma targets one of this year's biggest European IPOs with top-of-the-range share price
21 Mar 2024
IPO
Galderma, a skincare company that also has an R&D pipeline, is set to start trading on the SIX Swiss Exchange Friday at a premium price of CHF 53 ($59.31) per share, placing its IPO value at CHF 2.3 billion ($2.6 billion).
The Zug-based entity is mainly known for consumer brands such as Cetaphil and Differin. Last week, Galderma said it planned to price its public debut between CHF 49 to CHF 53 apiece. The shares will be listed as “GALD” on Friday.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.